Cancer & Heart Disease
Dr. Davis is a Clinical Assistant Professor in the Division of Cardiology at the University of British Columbia. She completed her MD, internal medicine residency, and cardiology fellowship at UBC, and completed additional training in advanced heart failure and transplant cardiology, cardio-oncology, and cardiac amyloidosis at Stanford University. Her research interests are focused on heart disease in cancer patients and on cardiac amyloidosis.
Lay summary of program/project:
Heart disease is an important limitation to the quality of life and survival of cancer patients and survivors. Not only do cancer and heart disease have many common risk factors, leading to the coexistence of the two diseases in a large segment of the population, but also cancer treatments can directly cause damage to the heart. The objectives of her research program are to measure the risk of heart disease in different cancer populations, to understand how cancer and cancer treatments affect the heart, and to develop new methods of prevention, diagnosis, and treatment of heart disease in cancer patients and cancer survivors.
Medical summary of program/project:
Cardiovascular disease is an important cause of morbidity and mortality among cancer patients and survivors, due to the existence of common risk factors for heart disease and cancer and to the direct and indirect cardiovascular toxicities of cancer therapies. Research to date has only begun to describe the true burden of cardiovascular disease in this population, and effective strategies for the prevention and treatment of heart disease in cancer survivors have not been well defined.
Dr. Davis’ research program aims to:
(1) describe the burden of cardiovascular disease in the oncology population;
(2) advance understanding of the pathophysiology of cancer treatment-associated heart disease through collaborations with translational research scientists;
(3) identify novel methods of risk stratification and early diagnosis of cardiotoxicity among patients receiving cancer therapies;
(4) develop therapeutic strategies for the prevention and treatment of cardiotoxicity through hypothesis-driven trials based on results from observational studies;
(5) utilize knowledge translation activities to optimize the delivery of cardiovascular care to cancer patients and survivors in Canada.